SG10202010665YA - Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders - Google Patents
Methods of treating alzheimer's disease, huntington's disease, autism, or other disordersInfo
- Publication number
- SG10202010665YA SG10202010665YA SG10202010665YA SG10202010665YA SG10202010665YA SG 10202010665Y A SG10202010665Y A SG 10202010665YA SG 10202010665Y A SG10202010665Y A SG 10202010665YA SG 10202010665Y A SG10202010665Y A SG 10202010665YA SG 10202010665Y A SG10202010665Y A SG 10202010665YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- autism
- huntington
- disorders
- methods
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 206010003805 Autism Diseases 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 title 1
- 208000023105 Huntington disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479593P | 2011-04-27 | 2011-04-27 | |
| US201161527744P | 2011-08-26 | 2011-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010665YA true SG10202010665YA (en) | 2020-11-27 |
Family
ID=47073094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013079603A SG194230A1 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| SG10202010665YA SG10202010665YA (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013079603A SG194230A1 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140107037A1 (OSRAM) |
| EP (2) | EP3679931A3 (OSRAM) |
| JP (1) | JP6035326B2 (OSRAM) |
| KR (5) | KR20190037359A (OSRAM) |
| CN (2) | CN108283712A (OSRAM) |
| AU (1) | AU2012249397B2 (OSRAM) |
| BR (1) | BR112013027554A2 (OSRAM) |
| CA (1) | CA2834286A1 (OSRAM) |
| EA (2) | EA201790653A1 (OSRAM) |
| HK (1) | HK1258231A1 (OSRAM) |
| MX (1) | MX357761B (OSRAM) |
| SG (2) | SG194230A1 (OSRAM) |
| WO (1) | WO2012149389A2 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740628C (en) | 2008-09-18 | 2018-05-01 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
| BR112012020142A2 (pt) | 2010-02-11 | 2020-08-18 | Northwestern University | moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos. |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| PE20151438A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| DK2951183T3 (da) | 2013-01-29 | 2019-06-03 | Aptinyx Inc | Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf |
| US9828384B2 (en) | 2013-01-29 | 2017-11-28 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| ES2618421T3 (es) | 2013-01-29 | 2017-06-21 | Aptinyx Inc. | Moduladores espiro-lactama del receptor NMDA y usos de los mismos |
| SG10201810496XA (en) | 2013-10-28 | 2018-12-28 | Naurex Inc | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| CN111920412A (zh) * | 2013-12-13 | 2020-11-13 | 西北大学 | 治疗脑部病症或鉴定与其相关的生物标记的方法 |
| CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
| BR112016030375A8 (pt) * | 2014-06-23 | 2021-07-13 | Univ Northwestern | uso de um composto no tratamento ou melhora da enxaqueca, no tratamento, supressão e/ou prevenção da depressão cortical e no tratamento ou melhora de uma lesão cerebral traumática |
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| MX378566B (es) | 2016-05-19 | 2025-03-11 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| EA201990424A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| KR102538803B1 (ko) | 2016-08-01 | 2023-06-01 | 앱티닉스 인크. | 스피로-락탐 nmda 조정제 및 그의 사용 방법 |
| SG11201900546UA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
| AU2017305240B2 (en) | 2016-08-01 | 2021-12-09 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| US11578072B2 (en) | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| KR102415692B1 (ko) | 2020-09-01 | 2022-07-05 | 건국대학교 글로컬산학협력단 | 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| CA2473536A1 (en) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| ATE499104T1 (de) * | 2005-03-24 | 2011-03-15 | Univ Emory | Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns |
| EP2257644B1 (en) * | 2008-02-20 | 2015-06-24 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism |
| CA2740628C (en) * | 2008-09-18 | 2018-05-01 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
| WO2011044089A2 (en) * | 2009-10-05 | 2011-04-14 | Joseph Moskal | Methods of treating depression and other related diseases |
-
2012
- 2012-04-27 SG SG2013079603A patent/SG194230A1/en unknown
- 2012-04-27 KR KR1020197008907A patent/KR20190037359A/ko not_active Ceased
- 2012-04-27 CN CN201711451914.XA patent/CN108283712A/zh active Pending
- 2012-04-27 KR KR1020187022910A patent/KR20180095096A/ko not_active Ceased
- 2012-04-27 CA CA2834286A patent/CA2834286A1/en not_active Abandoned
- 2012-04-27 SG SG10202010665YA patent/SG10202010665YA/en unknown
- 2012-04-27 KR KR1020217011613A patent/KR20210046843A/ko not_active Ceased
- 2012-04-27 EA EA201790653A patent/EA201790653A1/ru unknown
- 2012-04-27 MX MX2013012526A patent/MX357761B/es active IP Right Grant
- 2012-04-27 AU AU2012249397A patent/AU2012249397B2/en not_active Ceased
- 2012-04-27 BR BR112013027554A patent/BR112013027554A2/pt not_active Application Discontinuation
- 2012-04-27 EA EA201391581A patent/EA029999B1/ru unknown
- 2012-04-27 WO PCT/US2012/035547 patent/WO2012149389A2/en not_active Ceased
- 2012-04-27 US US14/114,376 patent/US20140107037A1/en not_active Abandoned
- 2012-04-27 KR KR1020207011211A patent/KR20200043534A/ko not_active Ceased
- 2012-04-27 KR KR1020137031028A patent/KR20140043078A/ko not_active Ceased
- 2012-04-27 EP EP20151676.2A patent/EP3679931A3/en not_active Withdrawn
- 2012-04-27 JP JP2014508130A patent/JP6035326B2/ja not_active Expired - Fee Related
- 2012-04-27 CN CN201280027349.3A patent/CN103974712A/zh active Pending
- 2012-04-27 EP EP12777016.2A patent/EP2701721A4/en not_active Ceased
-
2016
- 2016-04-14 US US15/098,985 patent/US20170049845A1/en not_active Abandoned
-
2018
- 2018-10-23 US US16/168,242 patent/US20190209642A1/en not_active Abandoned
-
2019
- 2019-01-14 HK HK19100591.2A patent/HK1258231A1/zh unknown
-
2020
- 2020-05-05 US US16/867,324 patent/US20210169964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6035326B2 (ja) | 2016-11-30 |
| EA201790653A1 (ru) | 2017-07-31 |
| AU2012249397A1 (en) | 2013-11-07 |
| CN103974712A (zh) | 2014-08-06 |
| US20140107037A1 (en) | 2014-04-17 |
| MX2013012526A (es) | 2014-04-16 |
| CA2834286A1 (en) | 2012-11-01 |
| KR20140043078A (ko) | 2014-04-08 |
| JP2014520072A (ja) | 2014-08-21 |
| EP2701721A4 (en) | 2015-12-16 |
| HK1258231A1 (zh) | 2019-11-08 |
| US20170049845A1 (en) | 2017-02-23 |
| EP2701721A2 (en) | 2014-03-05 |
| AU2012249397B2 (en) | 2017-03-30 |
| MX357761B (es) | 2018-07-23 |
| SG194230A1 (en) | 2013-12-30 |
| CN108283712A (zh) | 2018-07-17 |
| KR20210046843A (ko) | 2021-04-28 |
| WO2012149389A3 (en) | 2014-05-08 |
| EP3679931A3 (en) | 2020-10-14 |
| KR20180095096A (ko) | 2018-08-24 |
| EA201391581A1 (ru) | 2014-05-30 |
| EP3679931A2 (en) | 2020-07-15 |
| US20190209642A1 (en) | 2019-07-11 |
| KR20190037359A (ko) | 2019-04-05 |
| BR112013027554A2 (pt) | 2016-09-06 |
| EA029999B1 (ru) | 2018-06-29 |
| WO2012149389A2 (en) | 2012-11-01 |
| US20210169964A1 (en) | 2021-06-10 |
| KR20200043534A (ko) | 2020-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202010665YA (en) | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders | |
| IL311262B2 (en) | Methods for treating or preventing cholesterol-related disorders | |
| IL274469A (en) | Compositions, uses and methods for the treatment of metabolic disorders and diseases | |
| IL266648B (en) | A method for treating Parkinson's disease | |
| EP2707369A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| ZA201406209B (en) | Methods and compositions for treating huntington's disease | |
| EP2665696A4 (en) | PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOR-2-PROPENE | |
| ZA201502597B (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| SG11201403272YA (en) | Compositions and methods for treating alzheimer's disease | |
| IL229192A0 (en) | A method for treating vision disorders | |
| ZA201404500B (en) | Methods for diagnosing alzheimer's disease | |
| IL232710A0 (en) | l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders | |
| IL230441A0 (en) | Diagnosis of Alzheimer's disease | |
| SG10201703677VA (en) | Methods of treating s. aureus-associated diseases | |
| PL2901857T3 (pl) | Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu | |
| IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
| PL2691103T3 (pl) | Metoda leczenia zaburzeń skóry | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| HK1193358A (zh) | 一种治疗疾病或中枢神经系统病症的方法 | |
| AU2011900737A0 (en) | Methods of Treating a Disease or Condition of the Central Nervous System | |
| HK1195902A (en) | Compositions and methods for treating alzheimer's disease | |
| IL241482A0 (en) | A method for treating Parkinson's disease | |
| GB201106154D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201106142D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201113718D0 (en) | Treatment of Dupuytren's Disease |